Fig. 6

Circ_0001187 is epigenetically regulated, and combining chidamide and 5-azacytidine with METTL3 inhibitor synergistically suppresses AML cells. A The expression results of DOPEY2 in AML patients and healthy controls through qRT-PCR. B The expression results of DOPEY2 in paired samples from six follow-up AML patients at ND and HCR stage. C The results of correlation between the expression levels of Circ_0001187 and DOPEY2. D The expression levels of Circ_0001187 in AML cells cultured with 5-azacytidine (2.5, 5 and 10 μM, 24 h) or not by qRT-PCR. E The results of MSP by Agarose gel electrophoresis. F The expression levels of Circ_0001187 in AML cells cultured with chidamide (0.5, 1 and 2 μM, 24 h) or not by qRT-PCR. G ChIP‒qPCR showing the effect of chidamide on the histone acetylation levels of Circ_0001187 by promoter-1. H The expression levels of Circ_0001187 in AML cells cultured with CHi or 5-Aza or combination by qRT-PCR. I The effect of oe-Circ_0001187 on the apoptosis of AML cells cultured with METTL3 inhibitor, CHi or 5-Araz or combination. J-K The expression levels of Circ_0001187 in THP-1 cells transfected with si1/si2-EIF4A3 or oe-EIF4A3. L RIP assay to verify the physical interaction between EIF4A3 and the pre-mRNA of Circ_0001187 and Circ_0001947. M The results of RNA pull-down assays. N The expression level of EIF4A3 in AML patients and healthy controls through qRT-PCR. O The results of correlation between the expression levels of Circ_0001187 and EIF4A3. P-Q The results of correlation between the expression levels of RNF113A and EIF4A3. HCR: Hematological Complete remission; Ctrl: Control; ND: Newly diagnosed; R/R: relapsed-refractory; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: Not significant